secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0000950170-24-117578
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports 3 of 6 rHGG patients alive >1 year after CAN-3110 multiple injections
--------------------------------------------------------------------------------

- Phase 1b trial of CAN-3110 in recurrent high-grade glioma: 3/6 patients alive at 12.2, 13.0, and 18.7 months post-treatment.
- Data show improved survival vs. historical controls; biopsies reveal near absence of tumor cells with dense lymphocyte infiltrates.
- Radiologic pseudo-progression observed: post-treatment MRI enhancement despite tumor clearance on histology.
- Presented at 2024 IOVC; also disclosed new IL-12/IL-15 multimodal immunotherapy candidate from enLIGHTEN platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024117578/0000950170-24-117578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024117578/cadl-20241028.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer